Metabolic regulation of gene expression by histone lactylation

The Warburg effect, which originally described increased production of lactate in cancer, is associated with diverse cellular processes such as angiogenesis, hypoxia, polarization of macrophages and activation of T cells. This phenomenon is intimately linked to several diseases including neoplasia, sepsis and autoimmune diseases. Lactate, which is converted from pyruvate in tumour cells, is widely known as an energy source and metabolic by-product. However, its non-metabolic functions in physiology and disease remain unknown. Here we show that lactate-derived lactylation of histone lysine residues serves as an epigenetic modification that directly stimulates gene transcription from chromatin. We identify 28 lactylation sites on core histones in human and mouse cells. Hypoxia and bacterial challenges induce the production of lactate by glycolysis, and this acts as a precursor that stimulates histone lactylation.

Using MI macrophages that have been exposed to bacteria as a model system, we show that histone lactylation has different temporal dynamics from acetylation. In the late phase of MI macrophage polarization, increased histone lactylation induces homeostatic genes that are involved in wound healing, including Arg1. Collectively, our results suggest that an endogenous ‘lactate clock’ in bacterially challenged MI macrophages turns on gene expression to promote homeostasis. Histone lactylation thus represents an opportunity to improve our understanding of the functions of lactate and its role in diverse pathophysiological conditions, including infection and cancer.

Inspired by the discovery of various histone acylations derived from cellular metabolites, we predicted and identified lysine lactylation (Kla) as a new type of histone mark that can be stimulated by lactate (Fig. 1a). Initial evidence for histone Kla came from the observation of a mass shift of 72.021 Da on lysine residues in three proteolytic peptides that were detected in high-performance liquid chromatography (HPLC)–tandem mass spectrometry (MS/MS) analysis of trypically digested core histones from human MCF-7 cells (Fig. 1b and Extended Data Fig. 1d). This mass shift is the same as that caused by the addition of a lactyl group to the ε-amino group of a lysine residue.

To validate the existence of lysine lactylation in histones, we used four orthogonal methods. In the first two methods, we used HPLC–MS/MS analysis to compare a synthetic peptide with its in vivo-derived counterpart to determine whether the two versions of the peptide have the same chemical properties in terms of chromatographic elution in HPLC analysis and fragmentation pattern in MS/MS analysis. To achieve this, we generated three histone peptides bearing Kla modifications: H3K23-QLATKεAAR; H2BK5-PELKεSAPAPK; and H4K8-GGKεGLGK. Each pair of peptides co-eluted in HPLC and had comparable MS/MS spectra (Fig. 1b and Extended Data Fig. 1e). To confirm the modification further, we developed a pan anti-Kla antibody (Extended Data Fig. 1f, g). Immunoblots using the pan anti-Kla antibody confirmed the presence of histone Kla and showed that histone Kla levels were increased in a dose-dependent fashion in response to exogenous L-lactate (Extended Data Fig. 1h–j). Subsequent mass spectrometry analyses identified 26 and 16 histone Kla sites from human HeLa cells and mouse bone marrow-derived macrophages (BMDMs), respectively (Fig. 1c). Finally, metabolic labelling experiments using isotopic sodium L-lactate (13C3) followed by MS/MS analysis demonstrated that lysine lactylation can be derived from lactate (Extended Data Fig. 1k). Together, these experiments demonstrate that histone Kla is an in vivo protein post-translational modification derived from lactate.
Histone Kla sites in human HeLa cells

Histone Kla is regulated by glycolysis

Given that extracellular lactate can stimulate histone Kla, we hypothesized that modulation of intracellular lactate production would also affect histone Kla levels. We exposed MCF-7 and other cell lines to various concentrations of glucose, the major source of intracellular lactate. Both lactate production and histone Kla levels were induced by glucose in a dose-dependent manner (Fig. 2a, b and Extended Data Fig. 2a–c). Conversely, the non-metabolizable glucose analogue 2-deoxy-d-glucose (2-DG) decreased both lactate production and histone Kla (Fig. 2c, d). Sodium dichloroacetate (DCA) and oxametinil were used to inhibit lactate production by modulating the activities of pyruvate dehydrogenase and lactate dehydrogenase, respectively. As anticipated, intracellular levels of lactate were decreased by these two compounds (Fig. 2f) and levels of histone Kla were lowered (Fig. 2g, h). By contrast, rotenone—an inhibitor of the mitochondrial respiratory chain complex I that drives cells towards glycolysis—increased levels of both intracellular lactate and histone Kla (Fig. 2f, i). Quantification of histone Kla from DCA- and rotenone-treated MCF-7 cells (Extended Data Fig. 2i, j). 

Histone Kla sites in mouse BMDM cells

Histone Kla sites identified in human and mouse cells.

Hypoxia and bacterial exposure stimulate histone Kla

Increased glycolysis and lactate production are coupled with diverse cellular processes. To investigate whether histone Kla is regulated by glycolysis under physiological conditions, we chose two model systems: hypoxia and M1 macrophage polarization. In response to hypoxia, cells reprogram their metabolism by inhibiting oxidative phosphorylation...
Lactate regulates histone Kla. a–d, Intracellular lactate levels (a, d) and histone Kla levels (b, c) were measured from MCF-7 cells cultured in different concentrations of glucose or 2-DG in the presence of 25 mM glucose for 24 h. Lactate was measured by a lactate colorimetric kit. n = 3 biological replicates; statistical significance was determined using one-way ANOVA followed by Sidak’s multiple comparisons test. Immunoblots were performed using acid-extracted histone samples. The pan anti-Kla and anti Kac immunoblots indicate molecular masses between 10 and 15 kDa. Histone Kla levels but not Kac levels in MCF-7 cells (Fig. 2j, k and Extended Data Fig. 4e, f). The increase of histone Kla during M1 polarization is intrinsic and not due to paracrine effects, because replenishing cells with fresh media every 4 h did not affect Kla levels (Extended Data Fig. 4g). Increases in lactate production and histone Kla by hypoxia were attenuated by a lactate dehydrogenase inhibitor (oxamate) or a PDK1 inhibitor (DCA) (Extended Data Fig. 3a–d). Furthermore, we found that the induction of LDHA-specific inhibitor GNE-140 reduced 13C incorporation into histone Kla, but not Kac (Extended Data Fig. 4e, f). The increase of histone Kla levels was attenuated by DCA and PDK inhibitors (Extended Data Fig. 3g, h). In addition, the LDHA-specific inhibitor GNE-140 reduced 13C incorporation into histone Kla, but not Kac (Extended Data Fig. 4e, f). These results suggest that lactate is not simply a ‘waste product’ of glycolysis. Pro-inflammatory M1 macrophages undergo metabolic reprogramming towards aerobic glycolysis, resulting in lactate production, whereas anti-inflammatory M2 macrophages trigger a metabolic program of increased oxidative phosphorylation and fatty acid oxidation. Our discovery of histone Kla marks and their dynamics therefore suggests a role in regulating gene expression during M1 macrophage polarization.

To test this hypothesis, we examined the dynamics of lactate production and histone Kla marks during M1 macrophage polarization after treatment of BMDMs with lipopolysaccharide (LPS) and interferon-γ (IFNγ). We observed increased intracellular lactate levels 16–24 h after M1 activation (Fig. 3a), which correlated with increased histone Kla levels (Fig. 3b, c). By contrast, histone Kac levels were decreased at these time points (Fig. 3b, c). This differential pattern was confirmed by 13C-labelled histone Kac peaked 3 h after labelling and declined to a steady state, whereas histone Kla increased over the 24-h time course (Extended Data Fig. 4a–d). In addition, the LDHA-specific inhibitor GNE-140 reduced 13C incorporation into histone Kla, but not Kac (Extended Data Fig. 4e, f). The increase of histone Kla during M1 polarization is intrinsic and not due to paracrine effects, because replenishing cells with fresh media every 4 h did not affect Kla levels (Extended Data Fig. 4g). Increases in lactate production and histone Kla are also specific to M1 macrophages because they were not observed in M2-polarized BMDMs (Fig. 3d and Extended Data Fig. 4h), which are more reliant on fatty acid oxidation.

Histone Kla induces M2-like genes in M1 macrophages Histone modifications have an important role in the regulation of gene expression. To investigate histone Kla-associated genes 24 h after M1 polarization of macrophages, we performed RNA sequencing (RNA-seq) and paired chromatin immunoprecipitation followed by sequencing (ChIP-seq) using anti-H3K18la or anti-H3K18ac antibodies (the specificities of which were validated by dot blots).
ChIP and quantitative PCR (qPCR) assays (Extended Data Fig. 4i, j) and immunoblots (Extended Data Fig. 4k).

Our ChIP–seq data showed that H3K18la and H3K18ac were both enriched in promoter regions (±2 kb around transcriptional start sites) (Extended Data Fig. 4i) and were indicative of steady-state mRNA levels (Extended Data Fig. 4m, n). In addition, increased H3K18la (twofold increase) marked more genes than decreased H3K18la (twofold decrease), whereas the converse was true for the H3K18ac modification (Fig. 3e). Moreover, most genes marked by increased H3K18la were specific, because 68% of these genes (1,223 out of 1,787) did not display significantly increased H3K18ac (Fig. 3e, f and Supplementary Tables 2, 3). By contrast, no H3K18ac-specific genes were identified (Fig. 3e, f). Representative tracks from ChIP–seq studies are shown in Extended Data Fig. 4o, p.

To study correlations between H3K18la and gene expression, we performed RNA-seq analysis 0, 4, 8, 16 and 24 h after challenge with LPS and IFNγ (Extended Data Fig. 5a and Supplementary Table 4). As expected, inflammatory response genes (for example, Nos2) were induced as early as 4 h after challenge with LPS and IFNγ, and their expression levels steadily declined at later time points (Fig. 3g). Notably, the 1,223 genes specifically marked by increased H3K18la were more likely to be activated or reactivated at later time points (16 or 24 h) during M1 polarization (Fig. 3h and Extended Data Fig. 5a–c), which correlated well with the induction of intracellular lactate and histone Kla levels at these later time points (Fig. 3a–c). Gene Ontology (GO) analysis revealed that these H3K18la-specific genes were enriched in biological pathways that are independent of inflammation (Extended Data Fig. 5d). One of these enriched pathways was wound healing (for example, Arg1), which has been associated with the M2-like phenotype (Fig. 3h and Extended Data Fig. 5d). To corroborate these findings with more physiologically relevant stimuli, we treated BMDMs (M0) with live or dead Gram-negative bacteria (Escherichia coli, Acinetobacter baumannii and Pseudomonas aeruginosa) to stimulate M1 polarization. Similar to treatment with LPS, bacteria induced lactate production and global histone Kla but not histone Kac levels (Fig. 3i and Extended Data Fig. 5e, f), and the kinetics of early cytokine and late Arg1 expression were maintained (Fig. 3j and Extended Data Fig. 5g–j).

Arginine metabolism is a key catabolic and anabolic process that is regulated during macrophage polarization. M1 macrophages are thought to have low levels of ARG1 and metabolize arginine via nitric oxide synthase (iNOS) and ARG1, whereas M2 macrophages have high levels of ARG1, which produces ornithine to facilitate wound healing. Consistent with their RNA dynamics, ARG1 protein levels and activity were markedly increased 24–48 h after M1 polarization, whereas NOS2 protein levels and function peaked 12 h after M1 polarization and declined at later time points (Fig. 3k and Extended Data Fig. 5k). Collectively, these findings suggest that induction of lactate during M1 activation might promote a late-phase switch to a more homeostatic phenotype, which shares some similarity with the M2-like phenotype. Indeed, previous studies showed that treating BMDMs with lactate derived from tumour cells drives an M2-like phenotype that is characteristic of tumour-associated macrophages (TAMs)3. Using mouse cancer models, we observed a positive correlation between Arg1 expression and histone Kla levels, but not histone Kac levels in TAMs.
Histone Kla directly stimulates gene transcription

Our observed correlations between lactate, H3K18la and M2-like gene expression do not necessarily indicate that the histone Kla mark was a causative factor. Previous studies showed that exogenous lactate can alter Arg1 and Vegfa expression in unstimulated (M0) macrophages by added to BMDM cells 4 h after M1 polarization (LPS + IFNγ), and cells were collected at indicated time points after M1 polarization for intracellular lactate measurement (e), histone Kla immunoblot analysis (f), gene expression analysis (g) and H3K18la occupancy analysis by ChIP–qPCR (h). Data represent three independent experiments. f, g, n = 4 biological replicates. h, Data represent three technical replicates from pooled samples. Data in a, c, e, g and h are mean and s.e.m.; statistical significance was determined using multiple t tests corrected using the Holm–Sidak method (a, c, e, g).

Changes in gene expression during M1 polarization are caused by complex signalling cascades induced by LPS and IFNγ, including the induction of lactate and histone Kla. To substantiate the role of lactate and histone Kla in the regulation of gene expression, we manipulated levels of lactate and histone Kla. To examine whether histone Kla has a direct role in transcriptional regulation, we took advantage of a cell-free, recombinant chromatin-templated histone modification and transcription assay (Extended Data Fig. 9a) that was used previously to demonstrate direct transcriptional activation by p53- and p300-dependent histone Kac14. This assay, in which acetyl-CoA was replaced by l-lactyl-CoA (validated by HPLC and mass spectrometry; Extended Data Fig. 9h–k), demonstrated robust p300-dependent, p300-mediated H3 and H4 lactylation (Extended Data Fig. 9b) and a corresponding effect on transcription (Extended Data Fig. 9c). The effects paralleled those observed for acetyl-CoA-dependent histone acetylation and transcription. To confirm that transcription was directly mediated by lactylation of histones, rather than other proteins in the nuclear extract, recombinant chromatin was reconstituted with core histones bearing lysine-to-arginine mutations in histone tails15. Compared with wild-type histones, the H3 and H4 mutations, but not the H2A or H2B mutations, eliminated p300- and p53-dependent transcription (Extended Data Fig. 9d). Together, these findings suggest that, similar to histone acetylation, histone lactylation can directly promote gene transcription under the described conditions. To examine the potential activity of p300 as a histone Kla writer in cells, we overexpressed p300 in HEK293T cells and observed a modest increase in histone Kla levels (Extended Data Fig. 9e). By contrast, p300 deletion in HCT116 and HEK293T cells decreased histone Kla levels (Extended Data Fig. 9f, g). Although we cannot exclude an indirect effect by p300 in these cells, we manipulated levels of lactate and histone Kla. To substantiate the role of lactate and histone Kla in the regulation of gene expression, we manipulated levels of lactate and histone Kla. To examine whether histone Kla has a direct role in transcriptional regulation, we took advantage of a cell-free, recombinant chromatin-templated histone modification and transcription assay (Extended Data Fig. 9a) that was used previously to demonstrate direct transcriptional activation by p53- and p300-dependent histone Kac14. This assay, in which acetyl-CoA was replaced by l-lactyl-CoA (validated by HPLC and mass spectrometry; Extended Data Fig. 9h–k), demonstrated robust p300-dependent, p300-mediated H3 and H4 lactylation (Extended Data Fig. 9b) and a corresponding effect on transcription (Extended Data Fig. 9c).
macrophages switch to aerobic glycolysis, which is thought to support pro-inflammatory cytokine expression during M1 activation and produce the Warburg effect. Over time, this metabolic switch also increases intracellular lactate, which we show stimulates histone lysine lactylation 16–24 h after exposure to M1-polarizing stimuli. Histone lactylation is not required for the induction or suppression of pro-inflammatory genes. Instead, it serves as a mechanism to initiate expression of homeostatic genes that have been traditionally associated with M2-like macrophages. Our studies support a model in which the switch to aerobic glycolysis that occurs during M1 polarization starts a ‘lactate timer’ that uses an epigenetic mechanism to induce M2-like characteristics in the late phase, perhaps to assist with repairing collateral damage incurred by the host during infection.

High levels of lactate (for example, 40 mM in certain type of tumour tissue) is also associated with major hallmarks of diseases such as cancer. Given that the Kla modification can be stimulated by lactate and contribute to gene expression, the Kla modification is likely to fill an important knowledge gap in our understanding of diverse physiopathology (for example, infection, cancer) with which lactate is intimately associated.

Online content
Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41586-019-1678-1.

1. Pavlova, N. N. & Thompson, C. B. The emerging hallmarks of cancer metabolism. Cell Metab. 23, 27–47 (2016).
Materials
Pan anti-Kac (PTM-101), pan anti-Kla (PTM-1401), anti-H3K18a (PTM-1406), anti-H4K5a (PTM-1407) and anti-H4K8a (PTM-1405) antibodies were generated by PTM Bio Inc.; anti-histone H3 (ab12079), anti-H3K8ac (ab1191) and anti-H3K27ac (ab4729) antibodies were purchased from Abcam; Drosophila spike-in antibody (61686) and spike-in chromatin (S3083) were obtained from Active Motif; anti-LDHA (12025S) antibody was from Cell Signaling Technology; α-tubulin (05-829) and anti-LDH (ABC2927) antibodies were from MilliporeSigma; anti-HIF-1α (NB100-105) antibody was from Novus Biologicals; anti-NO (GTX130246) and anti-ARG1 (GTX190242) antibodies were purchased from GeneTex; anti-p300 (sc-584) was from Santa Cruz Biotechnology; anti-CD11b monoclonal antibody (MI/70), PE-cyanine7 (25-0112-82) and anti-F4/80 monoclonal antibody (B93, APC (17-4801-82) were from Thermofisher Scientific; lipopolysaccharides from Escherichia coli O111:B4 (L4391), sodium L-lactate (71718), L- (+) lactic acid (L4028), sodium dichloroacetate (347795), cobalt (II) chloride hexahydrate (C8661), rotenone (R8875), and acetyl-CoA (A2056) were purchased from Sigma-Aldrich; sodium lactate (13C6, 98%) (CLM-1396-1) were purchased from Cambridge Isotope Laboratories. Recombinant mouse IFNγ protein (485-MI-100) was modified sequencing grade trypsin was from Promega; lactate colorimetric assay kit II (K627-100), arginase activity colorimetric assay kit (K755-100), and nitric oxide synthase (NOS) activity assay kit (K205-100) were purchased from Biovision.

Methods
Cell culture
MCF-7, MDA-MB-231, HeLa, A549, HepG2, MEF and RAW 264.7 cells were obtained from the American Type Culture Collection and cultured in DMEM supplemented with 10% FBS and 1% GlutaMAX (GIBCO). Cells were routinely tested for mycoplasma contamination (MP0035, Sigma-Aldrich), and only negative cells were used in experiments. No specific cell line authentication was performed. For growth under hypoxic conditions, cells were grown in a specialized, humidified chamber equilibrated with 1% oxygen, 94% nitrogen, 5% carbon dioxide for the indicated time.

Mouse experiments
All animal use and experiments performed were approved by Institutional Animal Care and Use Committee (ACUP 72209) at the University of Chicago. Ldhα+ mice (Jackson Laboratory, 030112) and LysM-Cre mice (Jackson Laboratory, 004781) were used to generate LysM-Cre<sup>−/−</sup>Ldhα<sup>-/-</sup> and littermate control LysM-Cre<sup>−/−</sup>Ldhα<sup>+</sup> mice. The following primers were used for genotyping: Ldhα forward: CTGAGACACCCATG TGAGA and Ldhα reverse: AGCAACACTCCAAGTCAGGA. The primers were used for genotyping: Ldhα forward: CTGAGACACCCATG TGAGA and Ldhα reverse: AGCAACACTCCAAGTCAGGA. The primers were used for genotyping: Ldhα forward: CTGAGACACCCATG TGAGA and Ldhα reverse: AGCAACACTCCAAGTCAGGA. The primers were used for genotyping: Ldhα forward: CTGAGACACCCATG TGAGA and Ldhα reverse: AGCAACACTCCAAGTCAGGA. The primers were used for genotyping: Ldhα forward: CTGAGACACCCATG TGAGA and Ldhα reverse: AGCAACACTCCAAGTCAGGA. The primers were used for genotyping: Ldhα forward: CTGAGACACCCATG TGAGA and Ldhα reverse: AGCAACACTCCAAGTCAGGA.

Isotopic-labelled experiments
MCF-7 cells were cultured in DMEM high-glucose media plus 10% FBS. To be labelled by isotopic lactate, cells were treated with 10 mM of [13C] sodium L-lactate for 24 h. To be labelled by isotopic glucose, cells were switched to DMEM No-Glucose media (Gibco) for 24 h, followed by supplementation with 25 mM of U-[13C]<sub>6</sub>D-glucose and continued culturing for three passages. Histones were extracted, digested with trypsin, immunoprecipitated using a pan anti-Kla antibody and analysed by FlowJo v.10.4.1.

SilAC-based quantification
MCF-7 cells were cultured in either ‘heavy’ (L-Lys 13C<sub>6</sub>, 14N<sub>2</sub>) or ‘light’ (L-Lys 4C<sub>6</sub>, 14N<sub>2</sub>) DMEM, supplemented with 10% dialysed FBS (Sera-Laboratories International Inc.), for more than six passages, to achieve more than 99% labelling efficiency. Heavy-labelled and light-labelled cells were mixed in a 1:1 ratio. Histones were extracted, digested with trypsin,
immunoprecipitated using a pan anti-KIA antibody, and analysed by HPLC–MS/MS as described above. Quantification was analysed by Maxquant. Ratio H/L derived from Maxquant was then normalized by protein abundance.

**Synthesis of l-lactyl-CoA**

L-Lactic acid (90 mg, 1 mmol) was dissolved in 5 mL of freshly distilled CHCl₃. N-hydroxysuccinimide (115 mg, 1 mmol) was added to this solution, and the reaction mixture was sonicated to obtain a clear solution. Then, N,N′-dicyclohexylcarbodiimide (DCC, 227 mg, 1.1 mmol) was added. A white precipitate formed after addition. The reaction mixture was stirred at room temperature overnight. Then the white precipitate was filtered and washed with CH₂CN. The resulting organic solvent was evaporated by vacuum to afford crude product l-lactyl-NHS (170 mg, 91% yield), which was used in the next step without further purification.

**RNA-seq**

Gene expression values (RPKM) were normalized by subtracting the mean in every row, and hierarchically clustered with a Pearson correlation algorithm. Gene Ontology analysis (GOTERM_BP_DIRECT) was carried out using DAVID bioinformatics resources 6.823,24. The log2-transformed expression analysis was implemented using edgeR v.3.16.522 after retain-dated by FastQC v.0.11.4. All reads were mapped to the reference genome of Illumina iGenomes UCSC mm10 using HISAT2 v.2.1.021. Differential gene were counted by featureCounts v.1.5.0-p130, and then normalized in promoter regions (± 2 kb around transcriptional start sites) of each gene were counted by featureCounts v.1.5.0-p130, and then normalized in promoter regions (± 2 kb around transcriptional start sites) of each gene promoter regions in human cells: FOXO3 (previously known as FOXO3A) promoter: CAGTGTAGTTGCGACCTGGT, AAAAGCTTCTTCTTGTG CCT; FOXO3 downstream: TGGCAAGAACGCTGAAGAC, GGTCCCCA CAGACGCTTA; LDHA promoter: TAAGGGTGGGGGATACCTCT, CCCAAGGAAAAATGCAAGC. The following primers were used for qPCR analysis: Argf: CTCC AAGCGCAAGTCTTACAG, AGGAGCTGTCATAGGGAACATC; Vegfa: CAGGACAGAGGAGACAGAAGCT, CGTTCACAGGCCTGACAG CG; Ikb: GTTCTTGTGGAGATCCGTA, TTTGCGAAGTCATACG; Ltb: TTGTCAAGTGATGAAATGACC, CTTCTTGGTGATGTGCTGCT; Cnbk: CAGGTCAGAAAGGAAGACAGC, GGAGCTGTAATTCTCCTGAT; Cccx: CAAATGTCGGTCGTCATTTC, GGCTCGAGGAGGATGATCTTCAA; Tfna: CTCCTCACAAAGATCATCCTT, GCTACAGGGTGTCGACAG; and Rn18s (I85 rRNA): GTAACCCGTGAACCCCACT; CCATCCATCGTTAGGCG.

**ChIP–seq**

Native ChIP was carried out following the published protocol with spike-in for normalization purpose. Spike-in was carried out according to vendor protocols (61686, Active Motif). In brief, 50 ng of Spike-in chromatin (53083, Active Motif) was added to 25 µg of BMDM chromatin to incubate with 2 µg of antibody (61686, Active Motif) together with 4 µg of anti-H3K18ac or anti-H3K18ac antibodies. After 4 h of incubation at 4 °C, Protein A Sepharose (17-2580-01, GE Healthcare Life Sciences) was added and incubated for another 2 h, followed by sequential wash with buffer TSE I (0.1% SDS, 1% Triton X-100, 20 mM Tris-HCl pH 8.0, 150 mM NaCl), TSE II (0.1% SDS, 1% Triton X-100, 20 mM EDTA, 20 mM Tris-HCl pH 8.0, 500 mM NaCl), buffer III (0.25 M LiCl, 1% NP-40, 1% deoxoycholate, 1 mM EDTA, 10 mM Tris-HCl pH 8.0), and TE buffer (1 mM EDTA, 10 mM Tris-HCl pH 8.0). Chromatin DNA was finally eluted with buffer containing 1% SDS and 0.1 M NaHCO₃. The eluates were digested with RNase A (12091021, Thermo Fisher Scientific) and proteinase K (AM2546, Thermo Fisher Scientific). DNA was recovered using the QiAquick PCR purification kit (28106, Qiagen) according to the manufacturer’s instructions.

**Analysis of DNA replication events**

ChIP–seq libraries were constructed with an Accel-NGS 2S Plus DNA Library Kit (Swift Biosciences) according to the manufacturer’s protocol. The libraries were then amplified and assessed for fragment size using TapeStation (Agilent) and quantified using a Qubit dsDNA Assay Kit (Thermo Fisher Scientific). The indexed libraries were pooled and sequenced on a HiSeq4000 Sequencer (Illumina) using the 50-nucleotide single-read configuration.

**Bioinformatics analysis of ChIP–seq data**

Sequencing data was analyzed by FastQC v.0.11.4. All reads were mapped to the genome of Illumina iGenomes UCSC mm10 using Bowtie v.2.2.627,28, except that acetyl-CoA was used in place of acetyl-CoA and [α-32P]CTP was used in place of [α-32P]UTP. The H3KR, H4KR, H2AKR and H2BKSR histone mutants were the same as previously described. Histone modifications were monitored by immunoblot and transcription products were monitored by autoradiography as described.

**In vitro chromatin template-based histone modification and transcription assays**

Purification of recombinant proteins and chromatin assembly were performed as previously described, except that lactyl-CoA was used in place of acetyl-CoA and [α-32P]CTP was used in place of [α-32P]UTP. The H3KR, H4KR, H2AKR and H2BKRS histone mutants were the same as previously described. Purification of recombinant proteins and chromatin assembly were performed as previously described, except that lactyl-CoA was used in place of acetyl-CoA and [α-32P]CTP was used in place of [α-32P]UTP. The H3KR, H4KR, H2AKR and H2BKSR histone mutants were the same as previously described. Histone modifications were monitored by immunoblot and transcription products were monitored by autoradiography as described.

**RNA-seq**

Total RNA was extracted from BMDM cells activated as indicated using a RNeasy Plus Mini Kit (74134, Qiagen). Two to four micrograms of total RNA were used as starting material to prepare libraries using Illumina TruSeq Stranded mRNA Library Prep Kit Set A (RS-122-2101, Illumina). The size of the libraries was selected by using the Agencourt AMPure XP beads (A63882, Beckman Coulter), with average size of 400 bp. The libraries were sequenced using Illumina HiSeq 4000 (pair end 50 bp).

**Bioinformatics analysis of RNA-seq data**

Sequencing quality was evaluated by FastQC v.0.11.4. All reads were mapped to the reference genome of Illumina iGenomes UCSC mm10 using HISAT2 v.2.1.0.25,26,27. Differential expression analysis was implemented using edgeR v.3.16.527,28, after retaining only genes for which counts per million (cpm) was larger than one in four samples and normalizing the library sizes among samples using the TMM method of the edgeR package. Hierarchical clustering was performed and heat maps were generated using Perseus V.1.6.1.11 (http://www.coxdocs.org/doku.php?id=perseus:start). The log2-transformed gene expression values (RPKM) were normalized by subtracting the mean in every row, and hierarchically clustered with a Pearson correlation algorithm. Gene Ontology analysis (GOTERM_BP_DIRECT) was carried out using DAVID bioinformatics resources 6.823,24. The following primers were used for RT-qPCR analysis: Argf: CTCC AAGCGCAAGTCTTACAG, AGGAGCTGTCATAGGGAACATC; Vegfa: CAGGACAGAGGAGACAGAAGCT, CGTTCACAGGCCTGACAG CG; Ikb: GTTCTTGTGGAGATCCGTA, TTTGCGAAGTCATACG; Ltb: TTGTCAAGTGATGAAATGACC, CTTCTTGGTGATGTGCTGCT; Cnbk: CAGGTCAGAAAGGAAGACAGC, GGAGCTGTAATTCTCCTGAT; Cccx: CAAATGTCGGTCGTCATTTC, GGCTCGAGGAGGATGATCTTCAA; Tfna: CTCCTCACAAAGATCATCCTT, GCTACAGGGTGTCGACAG; and Rn18s (I85 rRNA): GTAACCCGTGAACCCCACT; CCATCCATCGTTAGGCG. The following primers were used for RT-qPCR analysis of gene promoter regions in human cells: FOXO3 (previously known as FOXO3A) promoter: CAGTGTAGTTGCGACCTGGT, AAAAGCTTCTTCTTGTG CCT; FOXO3 downstream: TGGCAAGAACGCTGAAGAC, GGTCCCCA CAGACGCTTA; LDHA promoter: TAAGGGTGGGGGATACCTCT, CCCAAGGAAAAATGCAAGC. The following primers were used for qPCR analysis of gene promoter regions in mouse cells: Argf/Argf-PTM: AAGCAGTTTGGCCTACAGCAG, GTAGAACGCTTGGTGAAGATGCTT; Argf-HRE-1kb: CAGGACAGAGGAGACAGAAGCT, CGTTCACAGGCCTGACAG CG; Argf-HRE-2kb: TTGTCTTCTTGAGTCTCCCTCAGG, AGCAAGCTT CATGCTGTGGA; Vegfa/Vegf-PTM: CGAAGCTTACAGCTTCTCCAG, AAATCTGCGGCTTCTCTTGCG; Vegfa/HRE-1kb: GGCAGCAAATTGTCCTTGGC ACT, CTCCGCAGACTCAGTCTGCTAG; Vegfa-HRE-2kb: ACCTGATCC GTAACCCCTGTCTACAGCA; Vegfa-HRE-3kb: GCAGAACCCTGTCTCCAGT, TTGAAGGGCTGACATGCTC.
AAGGTCTACGCAAGGTCGT, CGTACTCCCGAAGTCTCACACG; Glut1 (also known as Slc2a1): TAGATCCCCCTCCCTCTTG, GAACACGTAGCCTGC TCACA; gene desert: CTGCCAGGTTTAGAGGG, GCCAGATCATATT GCCGGTG.

Statistical analysis
No statistical methods were used to predetermine sample size. The significance of differences in the experimental data were determined using GraphPad Prism 7.0 software. All data involving statistics are presented as mean ± s.e.m. For data presented without statistics, experiments were repeated at least three times to ensure reproducibility, unless otherwise stated. The experiments were not randomized, and investigators were not blinded to allocation during experiments and outcome assessment.

Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this paper.

Data availability
The ChIP–seq and RNA–seq data have been made available at the Gene Expression Omnibus (GEO) repository under the accession number GSE115354. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE31 partner repository with the dataset identifier PXD014870. All other data are available from the authors upon reasonable request.

Acknowledgements
HEK293T p300 knockout cells were provided by X. Li. We thank S. Knochlin for brainstorming and critical reading of this manuscript. We thank K. Delaney and all other members of the Zhao and Becker laboratories for discussions and technical support. This work was supported by the University of Chicago, Nancy and Leonard Florsheim family fund (Y.Z.), NIH grants R01GM115961, R01DK18266 (Y.Z.), R01DK102960, R01HL137998 (L.B.), R01CA123525, R01DK071900 (R.G.R.), and NSF1808087 (Y.G.Z.).

Author contributions
Y.Z. conceived the project and developed the general ideas and research strategy. D.Z., L.B. and Y.Z. designed the experimental approach and composed the manuscript. D.Z. performed most of the experiments. Z.T. and R.G.R. contributed to mass spectrometry-related experiments and analysis; R.H., Z.Y. and B.R. performed the library construction and next-generation sequencing; R01CA123525, R01DK071900 (R.G.R.), and NSF1808087 (Y.G.Z.).

Competing interests
Y.Z. is a co-founder, board member, and advisor to PTM Bio Inc. L.B. is a co-founder and CSO of rMark Bio Inc., and a founder and CEO of Onchilles Pharma Inc.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41586-019-1678-1.

Correspondence and requests for materials
should be addressed to L.B. or Y.Z.

Peer review information
Nature thanks Luke O’Neill, Kathryn Wellen and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Reprints and permissions information is available at http://www.nature.com/reprints.
Extended Data Fig. 1 | Validation of histone lysine lactylation.

a, c, e. Extracted ion chromatograms from HPLC–MS/MS analysis of histone Kla peptides derived from cultured cells (in vivo), the synthetic counterparts, and their mixtures. b, d. MS/MS spectra of histone Kla peptides derived from in vivo, the synthetic counterparts, and their mixtures.
f, g. Antibody specificity tests by dot blot and competition assay. f. Dot blot was carried out with a pan anti-Kla antibody and the following peptide libraries. A1, A2, A3 and A4: dots contain 1, 4, 16 and 64 ng, respectively, of a peptide library containing a lactylated lysine residue. B1, B2, B3 and B4: dots contain 64 ng of a peptide library containing an unmodified (K), acetylated (Kac), propionylated (Kpr) and butyrylated (Kbu) lysine residue, respectively. C1, C2, C3 and C4: dots contain 64 ng of a peptide library containing a β-hydroxybutyrylated (Khb), 2-hydroxyisobutyrylated (Khi) fragments.
h – j. Exogenous lactate boosts histone Kla levels. Immunoblot analysis of histone Kla and Kac from human MCF-7 cells treated with indicated doses of L-lactate (h), and from human HeLa (i) and MDA-MB-231 (j) cells treated with 25 mM sodium chloride, sodium lactate or sodium acetate. k. MS/MS spectra of an isotopically labelled histone Kla peptide identified from MCF-7 cells cultured with 10 mM isotopic (13C3) sodium L-lactate for 24 h. Data in a–k represent three independent experiments.
Extended Data Fig. 2 | Histone Kla is modulated by the glycolysis pathway.

a–c, A549 (a), HeLa (b) and mouse embryonic fibroblast (MEF) (c) cells were cultured with indicated doses of glucose for 24 h, without pyruvate. Histone Kla and Kac were analysed by immunoblots using indicated antibodies.

d, MS/MS spectra of a U-13C6-glucose labelled histone Kla peptide and its unlabelled counterpart from MCF-7 cells.

e–h, Quantitative proteomic analysis of histone extracts from MCF-7 cells cultured in the presence of U-13C6 glucose for 6 h, 12 h, 24 h and 48 h, with or without 10 mM DCA. i–k, Histone Kla and Kac levels were analysed by immunoblots using whole-cell lysates from MCF-7, HepG2 and MEF cells exposed to 25 mM glucose for the indicated times. l, m, SILAC–MS/MS quantification of histone Kla and Kac marks from MCF-7 cells, comparing rotenone (10 nM, 24 h) versus DMSO treatment (l), and DCA (10 mM, 24 h) versus PBS treatment (m). SILAC ratio was normalized to protein abundance. Each dot in the scatter dot plot represents one identified peptide from core histone. Data are mean ± s.e.m. l, Kla: 1.121 ± 0.05084, n = 31; Kla: 1.599 ± 0.139, n = 25. m, Kac: 1.038 ± 0.03813, n = 49; Kla: 0.6627 ± 0.06376, n = 24. Statistical significance was determined using two-tailed Welch's t-test. Data in a–d, i–k represent three independent experiments. Data in e–h represent two independent experiments.
Extended Data Fig. 3 | Histone Kla is induced by hypoxia. a–d, Antibody specificity was analysed by dot blot assay. ac, acetyl lysine; bhb, β-hydroxybutyryl lysine; bu, butyryl lysine; cr, crotonyl lysine; hib, 2-hydroxyisobutyryl lysine; la, lactyl lysine; pr, propionyl lysine; succ, succinyl lysine; un, unmodified lysine. Kla library contains a mixture of CXXXKlaXXXX peptides, in which C is cysteine, X is a mixture of all 19 amino acids except for cysteine, and Kla is lactyl lysine. e, f, SILAC-MS/MS quantification of histone Kla and Kac marks from MCF-7 cells, comparing hypoxic (1% oxygen) and normoxic conditions. SILAC ratio was normalized to protein abundance. g, h, Immunoblots of histone Kla and Kac from human HeLa and mouse RAW 264.7 cells in response to hypoxia (1% oxygen) at the indicated time. i, j, Intracellular lactate levels (i) and histone Kla levels (j) were measured in MCF-7 cells comparing normoxia, hypoxia (1% oxygen, 24 h) and hypoxia in the presence of 10 mM oxamate or DCA. k, l, Intracellular lactate levels (k) and histone Kla levels (l) were compared in LDHA−/−, LDHB−/−, LDHA−/−LDHB−/− or wild-type (WT) HepG2 cells. Data are mean and s.e.m. from three biological independent samples; statistical significance was determined using one-way ANOVA followed by Dunnett’s multiple comparisons test. Data in a–d, g, h, i and j represent three independent experiments.
Extended Data Fig. 4 | See next page for caption.
Extended Data Fig. 4 | Histone Kla is induced during M1 macrophage polarization. a–f, Quantitative proteomic analysis of histone extracts from M0 and M1 macrophages (BMDMs) cultured in the presence of U-13C6-glucose for 3, 6, 12 and 24 h, or with 10 µM GNE-140 (LDHA/B inhibitor) for 24 h. g, Histone Kla and Kac levels were analysed by immunoblot 24 h after activation by LPS and IFNγ, with or without replenishing fresh media (containing LPS and IFNγ or not) every 4 h. h, BMDM cells were stimulated with PBS (M0), LPS plus IFNγ (M1), and IL-4 (M2) for 24 h. Intracellular lactate was measured using a lactate colorimetric kit. Data are mean and s.e.m. from three biological independent samples; statistical significance was determined using one-way ANOVA followed by Dunnett’s multiple comparisons test. i, j, Antibody specificity was evaluated by ChIP–qPCR. Competition was carried out by pre-incubating the indicated antibodies with a tenfold excess of corresponding peptides. k, H3K18la antibody specificity was shown by full immunoblot using total lysate from MCF-7 cells with or without 10 mM sodium l-lactate treatment for 24 h. l, H3K18la and H3K18ac are enriched in promoter regions. The promoter was defined as regions ± 2 kb around known transcription start sites. m, n, H3K18la and H3K18ac correlate with steady-state mRNA levels. The average ChIP signal intensity (read count per million mapped reads) for indicated antibodies is shown for genes with different expression levels (the top 25%, the second 25%, the third 25%, and the bottom 25% of RNA-seq counts). o, p, IGV tracks for Arg1 and Crem from ChIP–seq analysis, representing data from single experiment. Data in a–f represent two independent experiments. Data in g, i–k represent three independent experiments.
Extended Data Fig. 5 | See next page for caption.
Extended Data Fig. 5 | Histone K18a-specific genes are associated with late activated M2-like gene expression. **a, b,** Heat maps showing expression kinetics of total genes (a) and H3K18la-specific genes (b) during M1 macrophage polarization. *n* = 4 biological replicates. The colour key represents log₂-transformed fold change relative to the mean of each row. Arrows next to the heatmaps refer to late activated genes (16–24 h) from H3K18la-specific or total genes used for contingency test. **c,** Contingency table analysis (Fisher's exact tests) shows the relation between specific H3K18la enrichment (H3K18la log₂-transformed fold change ≥ 1 and H3K18ac log₂-transformed fold change ≤ 0.5) and late gene activation. **d,** Gene Ontology analysis (biological processes) of H3K18la-specific genes. Statistical significance was determined by modified Fisher’s exact test (EASE score) using DAVID bioinformatics resources 6.8; *n* = 1,223 genes. **e–j,** BMDM cells were infected with indicated Gram-negative bacteria for 24 h. Intracellular lactate (e) and histone Kla levels (f) were measured 24 h after bacterial challenge. *e, n* = 3 biological replicates; statistical significance was determined using one-way ANOVA followed by Dunnett’s multiple comparisons test. **g–j,** Gene expression was analysed by RT–qPCR at indicated time points after bacterial challenge. **k,** Activities of iNOS and ARG1 were analysed by and commercialized kits from BMDMs activated by the indicated stimuli. Data are mean and s.e.m. from three biological replicates. Data in **f and k** represent three independent experiments.
Extended Data Fig. 6 | Histone Kla levels are positively correlated with Arg1 expression in TAMs. 

**a**, The purity of TAMs and peritoneal macrophages (PMs) was confirmed by flow cytometry using CD11b and F4/80 antibodies. **b–e**, Data were quantified by FlowJo v.10.4.1. Histone Kla and Kac levels were analysed by immunoblots (b), intracellular lactate was measured using a lactate colorimetric assay kit (c), and gene expression of Arg1 and Vegfa were analysed by RT-qPCR (d, e) from FACS-sorted peritoneal macrophages and TAMs within the tumour from LLC and B16 tumours. Data in c–e are mean and s.e.m. n = 5 biological independent samples; statistical significance was determined using one-way ANOVA followed by Dunnett’s multiple comparisons test. Data in a and b represent five independent mice.
Extended Data Fig. 7 | Decreased lactate production lowered histone Kla levels and Arg1 expression during M1 polarization. a, b, Genotyping of Ldhafl/fl × LysM-Cre+/− mice. c, Genotype validation by LDHA immunoblot analysis. d–g, Gene expression analysis of cytokines by RT–qPCR at indicated time points after M1 polarization. h–m, Intracellular lactate levels (h) were analysed using a lactate colorimetric assay kit and global histone Kla levels (i) were measured by immunoblots 24 h after M1 polarization. Inhibitors were treated 30 min after M1 polarization. Gene expression was analysed by RT–qPCR at indicated time points after M1 polarization (j–m). Data are mean and s.e.m. from three biological replicates. Statistical significance was determined using one-way ANOVA followed by Dunnett’s multiple comparisons test. Data in a–c and i represent three independent experiments.
Extended Data Fig. 8 | Exogenous lactate activates M2-like gene expression through histone Kla. a–d, Exogenous lactate (LA) does not interfere with gene expression of inflammatory cytokines. Data are mean ± s.e.m. from four biological replicates. e, Number of lactate-activated H3K18la-specific genes at indicated times are shown in a Venn diagram. f, Gene Ontology analysis (biological processes) of lactate-induced H3K18la-specific genes at 16 and 24 h after M1 polarization. Statistical significance was determined by modified Fisher’s exact test (EASE score) using DAVID bioinformatics resources 6.8; n = 112 genes. g, Vegfa was induced by exogenous lactate during M1 macrophage polarization; n = 4 biological replicates; statistical significance was determined using multiple t-tests corrected using the Holm–Sidak method. h, H3K18la occupancy at the Vegfa promoter was analysed by ChIP–qPCR at indicated time and treatment; data represent three technical replicates from pooled samples. i–m, HIF1α is not required for histone Kla-mediated Arg1 induction during M1 polarization. i, Immunoblot of HIF1α at indicated time points after M1 polarization. j, Illustration of genomic loci targeted by Arg1 and Vegfa ChIP–qPCR primers. HRE indicates regions containing the putative HIF1α binding motif ‘ACGTG’. k–m, ChIP–qPCR analysis of HIF1α binding to indicated genomic locations; data represent three technical replicates from pooled samples. Data are mean and s.e.m. Data in i represent three independent experiments.
Extended Data Fig. 9 | Histone Kla directly stimulates gene transcription from recombinant chromatin in vitro. a, Protocol for assembly, modification and transcription of chromatin templates. b, P300 catalyses histone lactylation in a p53-dependent manner. c, Histone lactylation directly stimulates p53-dependent transcription from recombinant chromatin. d, H3 and H4 lysine-to-arginine (KR) mutations eliminate p300-dependent transcriptional activation by p53. Recombinant chromatin was assembled with wild-type or H3KR, H4KR, H2AKR or H2BKR mutant histones as indicated. e, HEK293T cells were transfected with vector or Flag-tagged p300 plasmid. At 48 h after transfection, whole-cell lysates were prepared and immunoblotted with indicated antibodies. f–g, Immunoblots of histone Kla and Kac levels in HCT116 (f) and HEK293T cells (g) in which p300 was genetically deleted. h–k, Quality control of synthesized l-lactyl-CoA. h, Illustration of l-lactyl-CoA structure. i, j, HPLC analysis of the synthesized l-lactyl-CoA. The UV detection wavelength was fixed at 214 and 254 nm. k, MALDI-mass spectrometry analysis of l-lactyl-CoA. Data in b–g and h–k represent three independent experiments.
Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

| n/a | Confirmed |
|-----|-----------|
| ☑ | The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| ☑ | A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| ☑ | The statistical test(s) used AND whether they are one- or two-sided |
| ☑ | Only common tests should be described solely by name; describe more complex techniques in the Methods section. |
| ☑ | A description of all covariates tested |
| ☑ | A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| ☑ | A full description of the statistical parameters including central tendency (e.g. mean) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| ☑ | For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted. Give P values as exact values whenever possible. |
| ☑ | For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| ☑ | For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| ☑ | Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated |

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

- Mass spectrometry: Thermo Xcalibur 3.0.63
- Flow cytometry: FACSDiva 10.5.3

Policy information about availability of data

- All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
  - Accession codes, unique identifiers, or web links for publicly available datasets
  - A list of figures that have associated raw data
  - A description of any restrictions on data availability

The ChiP-seq and RNA-seq data have been made available at the Gene Expression Omni Bus (GEO) repository under the accession number GSE115354. All other data are available from the authors upon reasonable request.
Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☐ Life sciences  ☐ Behavioural & social sciences  ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/hr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

| Sample size | Specific sample sizes are described in figures or figure legends for all experiments. The sample size used for animal experiment is based on previous experience from the Zhao and Becker labs. No statistical test was used to pre-determine sample size. |
|--------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Data exclusions | No samples or animals were excluded from the analyses.                                                                                                                                               |
| Replication | The number of repeats for each experiments are described in corresponding figure legends. All repeats support the same conclusion.                                                                     |
| Randomization | Cells or mice tissue were randomly assigned to groups (chemical compound/hypoxia/other treatments).                                                                                                  |
| Blinding | For animal related experiments, the investigators were divided into two groups: one group is responsible for collecting samples and the other group is responsible for experiment and outcome assessment. |

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

| Materials & experimental systems | n/a | Involved in the study |
|---------------------------------|-----|-----------------------|
| n/a                             | ☐  | Antibodies            |
| ☐  |     | Eukaryotic cell lines |
| ☐  |     | Palaeontology         |
| ☐  |     | Animals and other organisms |
| ☐  |     | Human research participants |
| ☐  |     | Clinical data         |

| Methods | n/a | Involved in the study |
|---------|-----|-----------------------|
| n/a     | ☐  | ChIP-seq              |
| ☐  |     | Flow cytometry        |
| ☐  |     | MRI-based neuroimaging |

Antibodies

The following antibodies were generated by PTM Bio Inc. [Chicago, IL]:

- pan anti-Kac [PTM-101], 1:2000 [WB]
- pan anti-Kia [PTM-1401], 1:2000 [WB]
- anti-H3K18a [PTM-1406], 1:5000 [WB], 4ug per ChIP
- anti-H4K8a [PTM-1405], 1:5000 [WB]
- anti-H4K5a [PTM-1407], 1:5000 [WB]

The following antibodies were generated by Abcam [Cambridge, MA]:

- anti-histone H3 [ab12079], 1:10000 [WB]
- anti-H3K18ac [ab1191], 1:10000 [WB], 4ug per ChIP
- anti-H3K27ac [ab4729], 1:5000 [WB]

The following antibodies were generated by Active Motif [Carlsbad, CA]:

- anti-drosophila spike-in antibody [81686], 2ug per ChIP

The following antibodies were generated by Cell Signaling Technology [Danvers, MA]:

- anti-LDHA [20125S], 1:2000 [WB]

The following antibodies were generated by Millipore Sigma [Burlington, MA]:

- anti-a-Tubulin [05-829], 1:5000 [WB]
- anti-LDHb [ABC927], 1:2000 [WB]
The following antibodies were generated by Novus Biologicals [Littleton, CO]:
anti-HIF-1α [N3100-105], 1:2000 [WB]

The following antibodies were generated by GeneTex [Irvine, CA]:
anti-iNos [GTX130246], 1:2000 [WB]
anti-Arg1 [GTX109242], 1:2000 [WB]

The following antibodies were generated by Santa Cruz Biotechnology, Inc [Dallas, TX]:
anti-p300 [sc-584], 1:2000 [WB]

The following antibodies were generated by Thermo Fisher Scientific [Waltham, MA]:
anti-CD11b Monoclonal Antibody (M1/70), PE-Cyanine7, eBioscience [25-0112-82], 0.125 µg/test [Flow]
anti-iF4/80 Monoclonal Antibody [BM8], APC, eBioscience [17-4801-82], 2 µg/test [Flow]

The following antibodies were generated by Jackson ImmunoResearch Laboratories [West Grove, PA]:
Peroxidase AffiniPure Goat Anti-Mouse IgG (H+L) [115-035-033], 1:10000 [WB]
Peroxidase AffiniPure Goat Anti-Rabbit IgG (H+L) [111-035-033], 1:10000 [WB]

Pan anti-Ki67 [PTM-101]:
Species: human, mouse; Application: Western Blot, Immunoprecipitation; Manufacturer’s web site: https://www.ptmblabs.com/product/ptm-101/

Pan anti-Ki67 [PTM-1401]:
Species: human, mouse; Application: Dot Blot, Western Blot, Immunoprecipitation; Validated in this paper.

Anti-H4K8a [PTM-1405]:
Species: human, mouse; Application: Western Blot; Validated in this paper.

Anti-H3K18a [PTM-1406]:
Species: human, mouse; Application: Dot Blot, Western Blot, ChIP; Validated in this paper.

Anti-H4K5a [PTM-1407]:
Species: human, mouse; Application: Dot Blot, Western Blot; Validated in this paper.

Anti-histone H3 (ab12079):
Species: human, mouse; Application: Western Blot; Manufacturer’s web site: https://www.abcam.com/histone-h3-antibody-chip-grade-ab12079.html

Anti-H3K18ac (ab11911):
Species: human, mouse; Application: Western Blot, ChIP; Manufacturer’s web site: https://www.abcam.com/histone-h3-acetyl-k18-antibody-chip-grade-ab11911.html

Anti-H3K27ac (ab4729):
Species: human, mouse; Application: Western Blot; Manufacturer’s web site: https://www.abcam.com/histone-h3-acetyl-k27-antibody-chip-grade-ab4729.html

Anti-LDH A [20125]:
Species: human; Application: Western Blot; Manufacturer’s web site: https://www.cellsignal.com/products/primary-antibodies/lactate-dehydrogenase/20125

Anti-a-Tubulin [05-829]:
Species: human, mouse; Application: Western Blot; Manufacturer’s web site: https://www.emdmillipore.com/US/en/product/Anti-Tubulin-Antibody-clone-DM1A,M_M_NF-05-829

Anti-LDH B [ABC927]:
Species: human, mouse; Application: Western Blot; Manufacturer’s web site: https://www.emdmillipore.com/US/en/product/Anti-LDH-B-Antibody,M_M_NF-ABC927

Anti-drosophila spike-n antibody (61886):
Species: drosophila; Application: ChIP; Manufacturer’s web site: https://www.activemotif.com/catalog/1091/chip-normalization

Anti-NOS [GTX130246]:
Species: mouse; Application: Western Blot; Manufacturer’s web site: https://www.genetex.com/Product/Detail/NOS-antibody/GTX130246

Anti-Arg1 [GTX109242]:
Species: mouse; Application: Western Blot; Manufacturer’s web site: https://www.genetex.com/Product/Detail/Arginase-1-antibody/GTX109242

Ant-p300 (N15) [sc-584]:
Species: human; Application: Western Blot; Manufacturer’s web site: https://www.scbt.com/scbt/product/p300-antibody-n-15
p300 (N-15) has been discontinued and replaced by p300 (F-4); sc-48343.
Eukaryotic cell lines

Policy information about [cell lines](#).

**Cell line sources**: HeLa, MCF-7, AS49, MDA-MB-231, HepG2, MEF, and RAW264.7 cells were obtained from the American Type Culture Collection.

**Authentication**: HeLa, MCF-7, AS49, MDA-MB-231, HepG2, MEF, and RAW264.7 cells were authenticated based on our vast experience working with these cell lines (such as cell morphology, culture conditions, etc.). Furthermore, we believe that the modification we described in the paper is widely exist in various cell lines, not specific to certain cell types.

**Mycoplasma contamination**: Cells were routinely tested for mycoplasma contamination, and only negative cells were used in experiments.

**Commonly misidentified lines**

[See ICCLAC register](#).

None of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICCLAC.

Animals and other organisms

Policy information about [studies involving animals; ARRIVE guidelines](#) recommended for reporting animal research.

**Laboratory animals**: Adult male mice (Mus musculus, C57Bl/6, 7-10 weeks old) were purchased from The Jackson Laboratory, and were used to generate bone marrow derived macrophages (BMDMs). Ldhaf1fl/fl mice [Jackson Laboratory, 030112] and lysMcre mice [Jackson Laboratory, 004781] were used to generate lysMcre+/- Ldhaf1fl/fl and littermate control lysMcre-/- Ldhaf1fl/fl mice.

**Wild animals**: The study did not involve samples collected from wild animals.

**Field-collected samples**: The study did not involve samples collected from the field.

**Ethics oversight**: All animal protocols were approved by Institutional Animal Care and Use Committee (IACUC) at the University of Chicago.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

ChIP-seq

**Data deposition**

[X] Confirm that both raw and final processed data have been deposited in a public database such as [GEO](#).

[X] Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

**Data access links**

May remain private before publication.

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115354

**Files in database submission**

GSM3176446_R1_148_peaks.broadPeak.gz
GSM3176447_R1_229_peaks.broadPeak.gz
GSM3176449_R1_151_peaks.broadPeak.gz
GSM3176450_R1_231_peaks.broadPeak.gz
GSE115354_ChIP-seq_normalization.txt.gz

**Genome browser session**

[Go](#).

N/A

**Methodology**

**Replicates**: ChIP-seq samples are prepared as one replicate, pooled from four mice.

**Sequencing depth**

| Replicate | Sequence depth |
|-----------|---------------|
| RH_148    | [unique reads: 21755076; spike-in reads: 310066] |
| RH_151    | [unique reads: 21006731; spike-in reads: 141688] |
| RH_229    | [unique reads: 35576826; spike-in reads: 52482] |
| RH_231    | [unique reads: 32948613; spike-in reads: 50470] |

**Antibodies**

The anti-H3K18ac antibody was generated by PTM Biolabs. The process for generating antibodies were described similarly in Cell, 2011: 146; p. 1016-1028. Mol Cell, 2015. 58(2); p. 203-15. Nat Chem Biol, 2014. 10(5); p. 365-70. except for using different immunogens.

The anti-H3K18ac antibody was purchased from Abcam[ab1191, lot GR 300534-1]
The evaluation of the antibody for specificity and ChIP grade is provided in the manuscript.

Spike-in information: spike-in chromatin [Active motif, Catalog No. 53083], spike-in antibody [Active motif, Catalog No. 51666]

Peaks were called using MACS version 2.2.1 under q value = 0.01.

Sequencing quality was evaluated by FastQC version 0.11.4. All reads were mapped to reference genome of Iillumina iGenomes UCSC mm10 using Bowtie version 2.2.5, and only uniquely mapped reads were retained. SAMtools version 0.1.19 was used to convert files to bam format, sort, and remove PCR duplicates. Peaks were called using MACS version 2.2.1 under q value = 0.01.

The number of peaks at the cutoff threshold in each sample:
- 21885 peaks in GSM3176446_RH_148_peaks.broadPeak.gz
- 41493 peaks in GSM3176447_RH_229_peaks.broadPeak.gz
- 16139 peaks in GSM3176449_RH_151_peaks.broadPeak.gz
- 42237 peaks in GSM3176450_RH_231_peaks.broadPeak.gz

Base called by Real-Time Analysis (RTA)

Reads were mapped to reference genome of Iillumina iGenomes UCSC mm10 using Bowtie version 2.2.6, and only uniquely mapped reads were retained.

SAMtools version 0.1.19 was used to convert files to bam format, sort, and remove PCR duplicates. Peaks were called using MACS version 2.2.1 under q value = 0.01. Uniquely mapped reads of each gene were counted by featureCounts version 1.5.0-p1, and normalized by corresponding uniquely mapped spiked-in ChIP read counts.

Flow Cytometry

Plots
- Confirm that:
  - The axis labels state the marker and fluorochrome used (e.g., CD4-FITC).
  - The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a ‘group’ is an analysis of identical markers).
  - All plots are contour plots with outliers or pseudocolor plots.
  - A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation

0.2 million cells were labeling with different fluorophore conjugated antibody at room temperature for 15mins, followed by two washes.

Instrument

Samples were analyzed using a FACSFaso™ II flow cytometer.

Software

Data were quantified by Flowjo v.10.4.1.

Cell population abundance

Purity for both TAM and Pmac are above 95% based on F4/80 and CD11b cell surface marker. Positive gating were determined by negative control.

Gating strategy

Cells were gated by FSC/SSC for total population → SSC-A/SSC-H for single cells → blue labeling for live cells population → F4/80 and CD11b double positive (compared to negative population) for purity check.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.